REACH REGULATION UPDATE 2024: What is expected

---

REACH regulation update 2024: what is expected

---

PIE: Pharmaceutical into Environment: a part of the One Health Approach

---

Essential use of chemicals. An update

---

PFAS: the biggest restriction proposal ever

---

Regulatory toxicology: more experts needed

---

The occupational exposure level determination based on toxicological approach

---

REACH REGULATION: What’s new about polymers

---

Environmental Risk Assessment of Medicinal Products: a complex issue

---

Essential use of chemicals. Opportunities or constrains

---

What the European Medicines Agency (EMA)’s choice of Digital Application Dataset Integration (DADI) means for Pharma

---

EU Green Chemical Legislation and its impact to industry

---

Extractable and Leachables in drug products – The toxicological and risk evaluation

---

One Health approach. Non only relevant but necessary!

---

Circular Economy, Substainability and Chemistry: a challenge!

---

Nitrosamine in drug products: an open discussion

---

REACH REGISTRATION DOSSIER: update still needed

---

SCIP, Waste framework directive and REACH regulation

---

REACH regulation update: Towards a REACH new version in 2022

---

The EU chemical strategy for sustainability towards a toxic-free environment

---

Microplastics: the environmental risk assessment, general criteria and approaches

---

Impurities in drugs: a toxicological approach is needed

---

Regulatory affairs: New challenges and new skills needed

---

REACH…and beyond!

---

Environmental Risk Assessment (ERA) of drugs: an overview

---

Microplastics: a new challenge for environment and human health

---

What’s new about BPR?

---

Endocrine Disrupting Substances (EDS) and implication in EU regulations

---

From “in vivo” studies to alternative methods. An update

---

Regulatory Toxicology: indispensable in many regulations, an overview

---

Pharma intermediates Overview on Light Registration procedure after last deadline

---

Brexit and REACH: an overview for a worst case scenario (no deal)

---